FDA Issues New Draft Guidance on Clinical Testing of Psychedelic Drugs

On June 23, 2023, FDA issued a first-of-its-kind draft guidance for sponsors of studies of psychedelic drugs. The guidance arrived just as the Psychedelic Science 2023 conference in Denver was wrapping up. Touted as the “largest psychedelic conference in history,” the conference drew over 12,000 people, including an array of medical professionals, government officials (i.e., Dr. Joshua Gordon, Director of the National Institute of Mental Health (NIMH), and Commander Gene Gunn in FDA’s Office of…
By: Manatt, Phelps & Phillips, LLP
Previous Story

Law Commission’s final report on digital assets: What’s new?

Next Story

Jackson National Life Insurance Company Files Notice of Two Data Breaches